Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. ASN-LABS
WARNING LETTER
•ASN-LABS•August 1, 2025

ASN-LABS – FDA Warning Letter, Aug 1, 2025

Record Details

The U.S. Food and Drug Administration (FDA) issued a warning letter to ASN-LABS on September 9, 2025, following a review of the company"s website conducted in August 2025. The investigation revealed that the Honolulu-based company is marketing unapproved and misbranded drug products, specifically retatrutide and semaglutide. The primary violations involve the distribution of retatrutide, which the FDA classifies as an unapproved "new drug." Under the Federal Food, Drug, and Cosmetic Act (FDCA), compounded drugs must meet specific criteria to be exempt from standard approval processes. Retatrutide fails these conditions because it is not an active ingredient in any FDA-approved medication, lacks an official quality monograph, and is not included on the authorized lists for pharmacy compounding. Additionally, the FDA found that ASN-LABS made false or misleading claims regarding its semaglutide products. By suggesting these products are the same as approved brand-name medications like Ozempic and Wegovy, the company misleads consumers, as compounded versions have not undergone the same rigorous FDA safety and efficacy review. The FDA further noted that these products lack adequate directions for safe use by non-professionals, contributing to their misbranded status. To resolve these issues, ASN-LABS must immediately correct the violations and ensure all operations comply with federal law. The company is required to submit a written response to the FDA within 15 working days, detailing the specific steps taken to address the concerns and prevent future occurrences. Failure to comply may lead to legal action, such as product seizures or injunctions.

Company
ASN-LABS
Inspection date
August 1, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · df7bf2e7-c50e-4b69-ac62-9b83e7dfa6f7

Violation Codes10
FD&C Act 501(a)(2)(B)FD&C Act 505(a)FD&C Act 502(a)21 U.S.C. 352(a)FD&C Act 505FD&C Act 201(g)(1)21 U.S.C. 321(g)(1)21 U.S.C. 331(c)21 CFR 201.115FD&C Act 301(c)

Full citation text and observation details available on the Dashboard.

Other documents for ASN-LABS
  • WARNING_LETTER - 2025-08-31August 31, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore ASN-LABS
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.